Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2036-07-01 | Direct | 125,000 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 125,000 · Balance 125,000 F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001193125-26-294852 · ownership.xml · derivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2036-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000950170-25-093470 · ownership.xml · derivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000950170-24-081603 · ownership.xml · derivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2034-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer. Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 21:46 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001493152-23-023342 · ownership.xml · derivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2033-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001493152-22-018687 · ownership.xml · derivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer. Read SEC document |
| March 28, 2022 Filed Mar 29, 2022 20:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares, no par value | 35,000 | $1.63 | $57,050.00 |
DisclosureSEC source: 0001493152-22-008029 · ownership.xml · nonDerivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · price: The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.48 to not more than $1.66. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:26 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001493152-21-015888 · ownership.xml · derivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001493152-21-009476 · ownership.xml · derivative · entry 1 Amin Dipti · CIK 0001856708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2031-04-19 F1 · derivative.exercise_date: This option shall vest in 36 monthly installments beginning on the one-month anniversary of the date of grant, subject to the reporting person's continuous service on the board of directors of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.